QNRX Key Statistics, Chart & Performance
The current stock price of QNRX is 12.21 USD. In the past month the price increased by 2.43%. In the past year, price decreased by -43.87%.
QNRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About QNRX
Company Profile
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Company Info
QUOIN PHARMACEUTICALS LT-ADR
23 Hata'as Street
Kfar Saba IL
CEO: Shai Yarkoni
Employees: 3
Phone: 97299741444
QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ
What does QUOIN PHARMACEUTICALS LT-ADR do?
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Can you provide the latest stock price for QUOIN PHARMACEUTICALS LT-ADR?
The current stock price of QNRX is 12.21 USD. The price decreased by -7.15% in the last trading session.
What is the dividend status of QUOIN PHARMACEUTICALS LT-ADR?
QNRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of QNRX stock?
QNRX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is QNRX stock listed?
QNRX stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of QUOIN PHARMACEUTICALS LT-ADR (QNRX)?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-31.74).
What is the next earnings date for QNRX stock?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) will report earnings on 2026-03-11, after the market close.
QNRX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to QNRX. When comparing the yearly performance of all stocks, QNRX is a bad performer in the overall market: 93.16% of all stocks are doing better.
QNRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QNRX. QNRX has a bad profitability rating. Also its financial health evaluation is rather negative.
QNRX Financial Highlights
Over the last trailing twelve months QNRX reported a non-GAAP Earnings per Share(EPS) of -31.74. The EPS increased by 77.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -214.33% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QNRX Forecast & Estimates
8 analysts have analysed QNRX and the average price target is 42.5 USD. This implies a price increase of 248.08% is expected in the next year compared to the current price of 12.21.